Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention

Paolo Gaetani, Vittorio Silvani, Giorgio Butti, Giovanni Spanu, Albino Rossi, Roberto Knerich

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Nitrosourea derivatives, such as BCNU and CCNU, are considered useful chemotherapeutic agents in malignant brain tumors combined therapy. Pulmonary toxicity is one of the more side effects demonstrated both in experimental animal models and in human autoptic findings. Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges. Authors present the results of a randomized, double-blind trial of 40 patients previously treated with surgery and radiotherapy and who subsequently underwent BCNU therapy for primary intracranial glioma. Patients underwent functional respiratory examinations at each chemotherapy course interval. Twenty patients received ambroxol (120 mg/day) for 40 days after chemotherapy course. Control patients received placebo with the same schedule and showed a significant reduction of pulmonary functional parameters (DLCO, MMEF, MEF 25%), whereas in the treated group there is no significant variation of these functional parameters. The mechanism of ambroxol is commonly related to the surfactant synthesis enhancement and to the action on bronchiolar pathways.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number3
DOIs
Publication statusPublished - 1987

Fingerprint

Brain Neoplasms
Ambroxol
Carmustine
Lung
Lomustine
Drug Therapy
Pulmonary Fibrosis
Surface-Active Agents
Glioma
Appointments and Schedules
Radiotherapy
Animal Models
Gases
Placebos
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention. / Gaetani, Paolo; Silvani, Vittorio; Butti, Giorgio; Spanu, Giovanni; Rossi, Albino; Knerich, Roberto.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 3, 1987, p. 267-271.

Research output: Contribution to journalArticle

@article{b192480187524176b9301c0ee47e5db2,
title = "Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention",
abstract = "Nitrosourea derivatives, such as BCNU and CCNU, are considered useful chemotherapeutic agents in malignant brain tumors combined therapy. Pulmonary toxicity is one of the more side effects demonstrated both in experimental animal models and in human autoptic findings. Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges. Authors present the results of a randomized, double-blind trial of 40 patients previously treated with surgery and radiotherapy and who subsequently underwent BCNU therapy for primary intracranial glioma. Patients underwent functional respiratory examinations at each chemotherapy course interval. Twenty patients received ambroxol (120 mg/day) for 40 days after chemotherapy course. Control patients received placebo with the same schedule and showed a significant reduction of pulmonary functional parameters (DLCO, MMEF, MEF 25{\%}), whereas in the treated group there is no significant variation of these functional parameters. The mechanism of ambroxol is commonly related to the surfactant synthesis enhancement and to the action on bronchiolar pathways.",
author = "Paolo Gaetani and Vittorio Silvani and Giorgio Butti and Giovanni Spanu and Albino Rossi and Roberto Knerich",
year = "1987",
doi = "10.1016/0277-5379(87)90069-1",
language = "English",
volume = "23",
pages = "267--271",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention

AU - Gaetani, Paolo

AU - Silvani, Vittorio

AU - Butti, Giorgio

AU - Spanu, Giovanni

AU - Rossi, Albino

AU - Knerich, Roberto

PY - 1987

Y1 - 1987

N2 - Nitrosourea derivatives, such as BCNU and CCNU, are considered useful chemotherapeutic agents in malignant brain tumors combined therapy. Pulmonary toxicity is one of the more side effects demonstrated both in experimental animal models and in human autoptic findings. Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges. Authors present the results of a randomized, double-blind trial of 40 patients previously treated with surgery and radiotherapy and who subsequently underwent BCNU therapy for primary intracranial glioma. Patients underwent functional respiratory examinations at each chemotherapy course interval. Twenty patients received ambroxol (120 mg/day) for 40 days after chemotherapy course. Control patients received placebo with the same schedule and showed a significant reduction of pulmonary functional parameters (DLCO, MMEF, MEF 25%), whereas in the treated group there is no significant variation of these functional parameters. The mechanism of ambroxol is commonly related to the surfactant synthesis enhancement and to the action on bronchiolar pathways.

AB - Nitrosourea derivatives, such as BCNU and CCNU, are considered useful chemotherapeutic agents in malignant brain tumors combined therapy. Pulmonary toxicity is one of the more side effects demonstrated both in experimental animal models and in human autoptic findings. Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges. Authors present the results of a randomized, double-blind trial of 40 patients previously treated with surgery and radiotherapy and who subsequently underwent BCNU therapy for primary intracranial glioma. Patients underwent functional respiratory examinations at each chemotherapy course interval. Twenty patients received ambroxol (120 mg/day) for 40 days after chemotherapy course. Control patients received placebo with the same schedule and showed a significant reduction of pulmonary functional parameters (DLCO, MMEF, MEF 25%), whereas in the treated group there is no significant variation of these functional parameters. The mechanism of ambroxol is commonly related to the surfactant synthesis enhancement and to the action on bronchiolar pathways.

UR - http://www.scopus.com/inward/record.url?scp=0023123750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023123750&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90069-1

DO - 10.1016/0277-5379(87)90069-1

M3 - Article

VL - 23

SP - 267

EP - 271

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 3

ER -